GlassScriptPhysician profile
James Vincent Lieb
NPI 1659340818
$3,018.77
in general payments reported to CMS, 2019-2025
38 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2021: $113 · 2023: $1,176 · 2024: $574 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,532 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,532.05 |
| Education | $223.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $356.36 | 2023-2025 | Opdivo, Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $219.27 | 2023-2025 | Calquence, Lynparza, Enhertu |
| Incyte Corporation | $218.63 | 2021-2025 | Monjuvi, Pemazyre, Jakafi |
| Merck Sharp & Dohme LLC | $216.48 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Mirati Therapeutics, INC. | $194.73 | 2023-2024 | Krazati |
| Janssen Biotech, INC. | $185.59 | 2019-2025 | Rybrevant, Erleada |
| Sobi, INC | $129.88 | 2025 | |
| Eisai INC. | $127.45 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.27 | 2023-2025 | Ninlaro, Iclusig, Alunbrig |
| Pharmaessentia USA Corporation | $100.15 | 2023-2025 | Besremi |
| Sumitomo Pharma America, INC. | $84.44 | 2023-2025 | Orgovyx |
| Daiichi Sankyo INC. | $79.43 | 2023-2025 | Enhertu, Datroway |
| Glaxosmithkline, LLC. | $78.01 | 2023-2025 | Ojjaara, Shingrix |
| Pharmacyclics LLC, An Abbvie Company | $76.95 | 2019 | |
| Pfizer INC. | $68.43 | 2023-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $65.74 | 2023-2025 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $64.65 | 2024-2025 | Verzenio, Retevmo, Jaypirca |
| Regeneron Healthcare Solutions, INC. | $58.87 | 2024-2025 | Libtayo |
| Asd Specialty Healthcare, LLC | $53.77 | 2019 | |
| Acrotech Biopharma INC. | $42.54 | 2021-2025 | Beleodaq |
| Beone Medicines USA, INC. | $38.91 | 2025 | Brukinsa, Tevimbra |
| Genentech USA, INC. | $36.79 | 2023-2024 | Phesgo |
| Genzyme Corporation | $36.45 | 2025 | |
| Novartis Pharmaceuticals Corporation | $31.92 | 2023 | |
| Array Biopharma INC | $29.27 | 2024 | Braftovi, Lorbrena, Mektovi |
| Tersera Therapeutics LLC | $28.04 | 2023 | Zoladex, Xermelo |
| Blueprint Medicines Corporation | $28.01 | 2023 | Ayvakit |
| Stemline Therapeutics INC. | $27.21 | 2025 | Elzonris |
| Novocure INC. | $26.43 | 2025 | Optune Lua (Novottf-200t) |
| Seagen INC. | $25.20 | 2023 | Padcev |
| Geron Corporation | $25.19 | 2025 | Rytelo |
| Servier Pharmaceuticals LLC | $24.93 | 2025 | |
| Kyowa Kirin, INC. | $23.90 | 2025 | |
| Rigel Pharmaceuticals, INC. | $21.51 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Abbvie INC. | $20.72 | 2023 | |
| Aveo Pharmaceuticals, INC. | $19.41 | 2024 | |
| Taiho Oncology, INC. | $18.13 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lieb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.